OncLive articlesOncLive articleshttps://www.onclive.com/newsOncLive articles© 2026 MJH Life Sciences™ and OncLive. All rights reserved.Mon, 26 Oct 2026 22:26:05 +00005en-usOncLive articles14447https://www.onclive.com/newshttps://www.onclive.com/logo.webp<![CDATA[Adjuvant Pembrolizumab Sustains DFS Benefit in Resected NSCLC]]>https://www.onclive.com/view/adjuvant-pembrolizumab-sustains-dfs-benefit-in-resected-nsclchttps://www.onclive.com/view/adjuvant-pembrolizumab-sustains-dfs-benefit-in-resected-nsclc<![CDATA[Adjuvant pembrolizumab continued to extend DFS in resected stage IB to IIIA NSCLC, though OS did not differ from placebo.]]>Mon, 26 Oct 2026 20:39:37 GMTOncLiveusOncLive Articles<![CDATA[ESMO On Location Day 2]]>https://www.onclive.com/view/esmo-on-location-day-2https://www.onclive.com/view/esmo-on-location-day-2<![CDATA[ESMO On Location Day 2 on the Conference floor ]]>Mon, 26 Oct 2026 20:00:00 GMTOncLiveusOncLive Articles<![CDATA[Extended DeLLphi-304 Follow-Up Confirms Durable Survival Benefit With Tarlatamab in Previously Treated SCLC]]>https://www.onclive.com/view/extended-dellphi-304-follow-up-durable-survival-tarlatamab-previously-treated-sclchttps://www.onclive.com/view/extended-dellphi-304-follow-up-durable-survival-tarlatamab-previously-treated-sclc<![CDATA[Longer DeLLphi-304 follow-up showed sustained OS, PFS, and response durability with tarlatamab in second-line small cell lung cancer.]]>Mon, 26 Oct 2026 19:29:44 GMTOncLiveusOncLive Articles<![CDATA[Rinatabart Sesutecan Improves Survival in Platinum-Resistant Ovarian Cancer]]>https://www.onclive.com/view/rinatabart-sesutecan-improves-survival-in-platinum-resistant-ovarian-cancerhttps://www.onclive.com/view/rinatabart-sesutecan-improves-survival-in-platinum-resistant-ovarian-cancer<![CDATA[Rinatabart sesutecan significantly improved PFS and OS vs investigator’s-choice chemotherapy in platinum-resistant ovarian cancer.]]>Mon, 26 Oct 2026 18:26:24 GMTOncLiveusOncLive Articles<![CDATA[Sac-TMT Improves PFS and OS, Is Under FDA Priority Review in Previously Treated Endometrial Cancer]]>https://www.onclive.com/view/sac-tmt-improves-pfs-and-os-is-under-fda-priority-review-in-previously-treated-endometrial-cancerhttps://www.onclive.com/view/sac-tmt-improves-pfs-and-os-is-under-fda-priority-review-in-previously-treated-endometrial-cancer<![CDATA[Sac-TMT extended survival and improved response rates vs chemotherapy in endometrial cancer that had progressed after chemotherapy and immunotherapy.]]>Mon, 26 Oct 2026 18:15:00 GMTOncLiveusOncLive Articles<![CDATA[Early ctDNA Clearance Linked to Improved Survival With Pembrolizumab Regimen in HPV-Negative HNSCC]]>https://www.onclive.com/view/early-ctdna-clearance-is-linked-to-improved-survival-with-pembrolizumab-plus-crt-in-hpv-negativehttps://www.onclive.com/view/early-ctdna-clearance-is-linked-to-improved-survival-with-pembrolizumab-plus-crt-in-hpv-negative<![CDATA[KEYNOTE-412 ctDNA data tie early clearance to longer survival with pembrolizumab plus chemoradiotherapy in HPV-negative head and neck cancer.]]>Mon, 26 Oct 2026 17:40:00 GMTOncLiveusOncLive Articles<![CDATA[KEYNOTE-C93 Shows PFS Benefit With First-Line Pembrolizumab Monotherapy in dMMR Endometrial Cancer]]>https://www.onclive.com/view/keynote-c93-shows-pfs-benefit-with-first-line-pembrolizumab-in-dmmr-endometrial-cancerhttps://www.onclive.com/view/keynote-c93-shows-pfs-benefit-with-first-line-pembrolizumab-in-dmmr-endometrial-cancer<![CDATA[Single-agent pembrolizumab extended progression-free survival vs carboplatin and paclitaxel in mismatch repair–deficient endometrial cancer.]]>Mon, 26 Oct 2026 17:28:32 GMTOncLiveusOncLive Articles<![CDATA[Savolitinib Combo Extends PFS in Frontline EGFR-Mutated NSCLC and MET Overexpression]]>https://www.onclive.com/view/savolitinib-combo-extends-pfs-in-frontline-egfr-mutated-nsclc-and-met-overexpressionhttps://www.onclive.com/view/savolitinib-combo-extends-pfs-in-frontline-egfr-mutated-nsclc-and-met-overexpression<![CDATA[Frontline savolitinib plus osimertinib improved progression-free survival vs osimertinib alone in EGFR-mutated, MET-overexpressing lung cancer.]]>Mon, 26 Oct 2026 17:07:31 GMTOncLiveusOncLive Articles<![CDATA[FDA Approves Talazoparib Plus Enzalutamide for Metastatic, HRR+ APMN/S Prostate Cancer]]>https://www.onclive.com/view/fda-approves-talazoparib-plus-enzalutamide-for-metastatic-hrr-apmn-s-prostate-cancerhttps://www.onclive.com/view/fda-approves-talazoparib-plus-enzalutamide-for-metastatic-hrr-apmn-s-prostate-cancer<![CDATA[The FDA approved talazoparib plus enzalutamide for HRR-positive, metastatic androgen pathway modulation–naive or -sensitive prostate cancer.]]>Mon, 26 Oct 2026 16:55:52 GMTOncLiveusOncLive Articles<![CDATA[Whole Genome Oncodetect MRD Test Is Now Available for Solid Tumors]]>https://www.onclive.com/view/whole-genome-oncodetect-mrd-test-is-now-available-for-solid-tumorshttps://www.onclive.com/view/whole-genome-oncodetect-mrd-test-is-now-available-for-solid-tumors<![CDATA[The next-generation, whole genome, tumor-informed Oncodetect MRD test tracks up to 5000 variants vs up to 200 in the first-generation assay.]]>Mon, 26 Oct 2026 16:55:00 GMTOncLiveusOncLive Articles<![CDATA[Ris-Rez Improves PFS in Relapsed/Refractory Osteosarcoma]]>https://www.onclive.com/view/ris-rez-improves-pfs-vs-gemcitabine-docetaxel-relapsed-refractory-osteosarcomahttps://www.onclive.com/view/ris-rez-improves-pfs-vs-gemcitabine-docetaxel-relapsed-refractory-osteosarcoma<![CDATA[Risvutatug rezetecan delayed progression vs gemcitabine and docetaxel in patients with osteosarcoma after 2 or more prior systemic therapies.]]>Mon, 26 Oct 2026 16:37:22 GMTOncLiveusOncLive Articles<![CDATA[Clinical Trial to Evaluate Blood Test for Early Detection of Breast Cancer]]>https://www.onclive.com/view/clinical-trial-to-evaluate-blood-test-for-early-detection-of-breast-cancerhttps://www.onclive.com/view/clinical-trial-to-evaluate-blood-test-for-early-detection-of-breast-cancer<![CDATA[A new clinical trial will investigate whether a simple blood test could help detect breast cancer as early as Stage I.]]>Mon, 26 Oct 2026 16:00:00 GMTOncLiveusOncLive Articles<![CDATA[Trastuzumab Pamirtecan Improves PFS in HR+, HER2-Low Metastatic Breast Cancer]]>https://www.onclive.com/view/trastuzumab-pamirtecan-improves-pfs-in-hr-her2-low-metastatic-breast-cancerhttps://www.onclive.com/view/trastuzumab-pamirtecan-improves-pfs-in-hr-her2-low-metastatic-breast-cancer<![CDATA[Phase 3 data showed a significant PFS improvement with trastuzumab pamirtecan vs chemotherapy in HR-positive, HER2-low metastatic breast cancer.]]>Mon, 26 Oct 2026 15:20:31 GMTOncLiveusOncLive Articles<![CDATA[FDA Grants Breakthrough Therapy Designation to Enzomenib in R/R KMT2A-Rearranged Acute Leukemia]]>https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-enzomenib-in-r-r-kmt2a-rearranged-acute-leukemiahttps://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-enzomenib-in-r-r-kmt2a-rearranged-acute-leukemia<![CDATA[The FDA granted breakthrough therapy designation to enzomenib for relapsed/refractory acute leukemia with a KMT2A rearrangement.]]>Mon, 26 Oct 2026 15:18:41 GMTOncLiveusOncLive Articles<![CDATA[Dr Swiecicki on First-Line Amivantamab Plus Pembrolizumab and Carboplatin in HNSCC]]>https://www.onclive.com/view/dr-swiecicki-on-first-line-amivantamab-plus-pembrolizumab-and-carboplatin-in-hnscchttps://www.onclive.com/view/dr-swiecicki-on-first-line-amivantamab-plus-pembrolizumab-and-carboplatin-in-hnscc<![CDATA[Paul L. Swiecicki, MD, discusses first-line amivantamab plus pembrolizumab and carboplatin in recurrent/metastatic head and neck cancer.]]>Mon, 26 Oct 2026 15:14:45 GMTOncLiveusOncLive Articles<![CDATA[Dr Long on INTerpath-001 Data for Intismeran Autogene Plus Pembrolizumab in Resected Melanoma]]>https://www.onclive.com/view/dr-long-on-interpath-001-data-for-intismeran-autogene-plus-pembrolizumab-in-resected-melanomahttps://www.onclive.com/view/dr-long-on-interpath-001-data-for-intismeran-autogene-plus-pembrolizumab-in-resected-melanoma<![CDATA[Georgina V. Long, AO, BSc, PhD, MBBS, discusses phase 3 INTerpath-001 data for adjuvant intismeran autogene plus pembrolizumab in melanoma.]]>Mon, 26 Oct 2026 15:00:00 GMTOncLiveusOncLive Articles<![CDATA[Five Under 5: Top Oncology Videos for the Week of 10/18]]>https://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-10-18https://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-10-18<![CDATA[The top 5 OncLive TV videos of the week cover insights in CRC at ESMO 2026, dMMR rectal cancer, chronic neutropenia, pediatric LGG, and MSS CRC.]]>Mon, 26 Oct 2026 14:15:49 GMTOncLiveusOncLive Articles<![CDATA[Niraparib/Dostarlimab Plus CRT Displays Efficacy but Has Toxicity Concerns in Locally Advanced HNSCC]]>https://www.onclive.com/view/niraparib-dostarlimab-plus-crt-displays-efficacy-but-has-toxicity-concerns-in-locally-advanced-hnscchttps://www.onclive.com/view/niraparib-dostarlimab-plus-crt-displays-efficacy-but-has-toxicity-concerns-in-locally-advanced-hnscc<![CDATA[Adding niraparib and dostarlimab to definitive CRT improved 1-year PFS in cisplatin-fit patients, although toxicity drove frequent discontinuations.]]>Mon, 26 Oct 2026 14:10:18 GMTOncLiveusOncLive Articles<![CDATA[Access, Monitoring, and Open Questions in TGCT Management]]>https://www.onclive.com/view/access-monitoring-and-open-questions-in-tgct-managementhttps://www.onclive.com/view/access-monitoring-and-open-questions-in-tgct-management<![CDATA[Dale R. Shepard, MD, PhD, of Cleveland Clinic, and Alexander B. Christ, MD, of UCLA Health, discuss practical management of tenosynovial giant cell tumor (TGCT) with R. Lor Randall, MD, FACS, of UC Davis Health.]]>Mon, 26 Oct 2026 13:33:00 GMTOncLiveusOncLive Articles<![CDATA[Pimicotinib MANEUVER Data and Treatment Around Joint Replacement]]>https://www.onclive.com/view/pimicotinib-maneuver-data-and-treatment-around-joint-replacementhttps://www.onclive.com/view/pimicotinib-maneuver-data-and-treatment-around-joint-replacement<![CDATA[Dale R. Shepard, MD, PhD, of Cleveland Clinic, reviews the phase 3 MANEUVER trial of pimicotinib, an investigational once-daily colony-stimulating factor 1 receptor (CSF1R) inhibitor under US Food and Drug Administration review for tenosynovial giant cell tumor (TGCT), with R. Lor Randall, MD, FACS, of UC Davis Health, and Alexander B. Christ, MD, of UCLA Health.]]>Mon, 26 Oct 2026 13:32:57 GMTOncLiveusOncLive Articles<![CDATA[Molecular Testing and Reporting of Exon 20 Insertions]]>https://www.onclive.com/view/molecular-testing-and-reporting-of-exon-20-insertionshttps://www.onclive.com/view/molecular-testing-and-reporting-of-exon-20-insertions<![CDATA[Exon 20 EGFR insertions often go misreported, driving suboptimal inhibitor use; experts explain why NGS and liquid testing improve lung cancer treatment choices.]]>Mon, 26 Oct 2026 12:05:00 GMTOncLiveusOncLive Articles<![CDATA[Symptom-Driven Treatment Decisions]]>https://www.onclive.com/view/symptom-driven-treatment-decisionshttps://www.onclive.com/view/symptom-driven-treatment-decisions<![CDATA[Dale R. Shepard, MD, PhD, of Cleveland Clinic, compares the 2 approved colony-stimulating factor 1 receptor (CSF1R) inhibitors for tenosynovial giant cell tumor (TGCT), pexidartinib and vimseltinib, with R. Lor Randall, MD, FACS, of UC Davis Health, and Alexander B. Christ, MD, of UCLA Health.]]>Mon, 26 Oct 2026 12:00:00 GMTOncLiveusOncLive Articles<![CDATA[Sustained Benefit of Adjuvant Olaparib in Women with Germline BRCA1- and BRCA2-associated High-risk HER2-negative Early Breast Cancer: Updated Results from the OlympiA Phase III Trial ]]>https://www.onclive.com/view/sustained-benefit-of-adjuvant-olaparib-in-women-with-germline-brca1--and-brca2-associated-high-risk-her2-negative-early-breast-cancer-updated-results-from-the-olympia-phase-iii-trialhttps://www.onclive.com/view/sustained-benefit-of-adjuvant-olaparib-in-women-with-germline-brca1--and-brca2-associated-high-risk-her2-negative-early-breast-cancer-updated-results-from-the-olympia-phase-iii-trial<![CDATA[Rapid readout: 6-year Olympia data confirm adjuvant olaparib boosts survival in BRCA1/2 high-risk early breast cancer, with reassuring long-term safety.]]>Mon, 26 Oct 2026 12:00:00 GMTOncLiveusOncLive Articles<![CDATA[Biology and Subtypes of EGFR Exon 20 Insertions]]>https://www.onclive.com/view/biology-and-subtypes-of-egfr-exon-20-insertionshttps://www.onclive.com/view/biology-and-subtypes-of-egfr-exon-20-insertions<![CDATA[Explore evolving first- and later-line treatments for EGFR exon 20 insertion NSCLC, including new targeted agents, chemo combos, and mutation-specific research.]]>Mon, 26 Oct 2026 12:00:00 GMTOncLiveusOncLive Articles<![CDATA[Torvu-Sam Elicits Responses & Manageable Safety Across FRα Expression Levels in PROC]]>https://www.onclive.com/view/torvutatug-samrotecan-elicits-responses-across-fra-expression-levels-in-platinum-resistanthttps://www.onclive.com/view/torvutatug-samrotecan-elicits-responses-across-fra-expression-levels-in-platinum-resistant<![CDATA[Updated FONTANA data show torvu-sam activity across FRα expression levels in platinum-resistant ovarian cancer.]]>Mon, 26 Oct 2026 10:43:26 GMTOncLiveusOncLive Articles<![CDATA[ESMO On Location Day 1 ]]>https://www.onclive.com/view/esmo-on-location-day-1https://www.onclive.com/view/esmo-on-location-day-1<![CDATA[ESMO On Location Day 1 on the Conference floor ]]>Sun, 25 Oct 2026 20:04:59 GMTOncLiveusOncLive Articles<![CDATA[Ivonescimab Plus Chemotherapy Represents a New SOC in First-Line Biliary Tract Cancer]]>https://www.onclive.com/view/ivonescimab-plus-chemotherapy-improves-os-vs-durvalumab-plus-chemotherapy-in-first-line-biliaryhttps://www.onclive.com/view/ivonescimab-plus-chemotherapy-improves-os-vs-durvalumab-plus-chemotherapy-in-first-line-biliary<![CDATA[In HARMONi-GI1, ivonescimab plus chemotherapy extended survival over durvalumab plus chemotherapy in untreated advanced biliary tract cancer.]]>Sun, 25 Oct 2026 18:55:58 GMTOncLiveusOncLive Articles<![CDATA[Dr Chase on the Potential Role of B7-H4–Targeted ADCs in Platinum-Resistant Ovarian Cancer]]>https://www.onclive.com/view/dr-chase-on-the-potential-role-of-b7-h4-targeted-adcs-in-platinum-resistant-ovarian-cancerhttps://www.onclive.com/view/dr-chase-on-the-potential-role-of-b7-h4-targeted-adcs-in-platinum-resistant-ovarian-cancer<![CDATA[Dana M. Chase, MD, discusses updated BEHOLD-1 data for mocertatug rezetecan and where B7-H4–targeted ADCs may fit in platinum-resistant ovarian cancer.]]>Sun, 25 Oct 2026 18:25:00 GMTOncLiveusOncLive Articles<![CDATA[CLARITY-Gastric01 Shows OS Benefit With Sonesitatug Vedotin in Pretreated CLDN18.2+ Gastroesophageal Carcinoma]]>https://www.onclive.com/view/clarity-gastric01-shows-os-benefit-with-sonesitatug-vedotin-in-pretreated-cldn18-2-gastroesophageal-carcinomahttps://www.onclive.com/view/clarity-gastric01-shows-os-benefit-with-sonesitatug-vedotin-in-pretreated-cldn18-2-gastroesophageal-carcinoma<![CDATA[Sonesitatug vedotin is a potential new SOC in select Claudin 18.2–positive gastroesophageal carcinoma.]]>Sun, 25 Oct 2026 17:59:23 GMTOncLiveusOncLive Articles<![CDATA[Divarasib Improves Survival and Paves Way for New SOC in Pretreated KRAS G12C–Mutated NSCLC]]>https://www.onclive.com/view/divarasib-improves-pfs-and-os-vs-sotorasib-or-adagrasib-in-pretreated-kras-g12c-mutated-nsclchttps://www.onclive.com/view/divarasib-improves-pfs-and-os-vs-sotorasib-or-adagrasib-in-pretreated-kras-g12c-mutated-nsclc<![CDATA[Divarasib extended survival over first-generation KRAS G12C inhibitors in a head-to-head phase 3 trial in previously treated lung cancer.]]>Sun, 25 Oct 2026 17:54:12 GMTOncLiveusOncLive Articles